options, page-7

Dont base your decision making on this (options being extended). Its not uncommon for options to time out. The saying “The larger the risk the larger the return” applies particulary to options. They have far more risk than heads. The good news is, the conversion price from the option now, is at a discount to what it will be at expirey, due to low SP.

The trials still going ahead is not unusual either. Medical research still needs to go on. Its a totally different category to elective surgery etc. And, if the company had any idea that trials would be delayed, they would have to announce that. They have announced that they are still a goer. So thats what we have now.

The way forward now is all dependent on the individual. What is your risk appetite? Are you willing to wait and see what happens with trial data, or do you need and cut and run from the options now. Research some other biotech companies that have recently made trial announcements, and have a look at what happened to the SP in the run up tom and post announcement. See if that allows you to select some target prices.

Hang in there everybody. One day the virus thing will be something in the past.